{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:23:50Z","timestamp":1767597830728,"version":"3.41.2"},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunity Inflam &amp;amp; Disease"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The aim of the study is to investigate the role of serum inflammatory factors and T\u2010cell subsets in the diagnosis of recurrence in epithelial ovarian cancer patients and the effect of olaparib on inflammatory factor and T\u2010lymphocyte subsets in patients with recurrent epithelial ovarian cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, 100 patients diagnosed as recurrent epithelial ovarian cancer in our hospital and 100 patients without recurrent epithelial ovarian cancer in the same period were selected. According to the treatment plan, the recurrent patients were divided into conventional therapy group (Paclitaxel and Carboplatin) and combined therapy group (Paclitaxel, Carboplatin, and olaparib). The levels of serum inflammatory factors were evaluated by enzyme\u2010linked immunosorbent assay. The peripheral blood T\u2010lymphocyte subsets in each group were detected by flow cytometry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with nonrecurrent patients, recurrent patients have higher serum interleukin\u20106 (IL\u20106) and tumor necrosis factor\u2010\u03b1 (TNF\u2010\u03b1) levels (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05), and lower interferon\u2010\u03b3 (IFN\u2010\u03b3) level and the CD4+\/CD8+ ratio. After adjusting for confounding factors, the results showed that the serum IL\u20106, IFN\u2010\u03b3, and TNF\u2010\u03b1 levels were influencing factors of recurrence in epithelial ovarian cancer patients. The area under the receiver operating curve and the sensitivity of serum TNF\u2010\u03b1 in predicting ovarian cancer recurrence were higher than those of IL\u20106 and IFN\u2010\u03b3. After secondary chemotherapy and\/or olaparib maintenance treatment, the IL\u20106 (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001) and TNF\u2010\u03b1 (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001) levels in combined therapy group were lower than those in the conventional therapy, whereas the IFN\u2010\u03b3 level (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001), the CD4+ T\u2010cell proportion (<jats:italic>p<\/jats:italic>\u2009=\u2009.0069) and the CD4+\/CD8+ ratio (<jats:italic>p<\/jats:italic>\u2009=\u2009.0201) were higher than those in the conventional therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The serum IL\u20106, TNF\u2010\u03b1, and IFN\u2010\u03b3 levels were closely related to the recurrence of ovarian cancer. Olaparib maintenance treatment can significantly decrease the IL\u20106 and TNF\u2010\u03b1 level, and increase IFN\u2010\u03b3 level and the CD4+\/CD8+ ratio in patients with recurrent ovarian cancer.<\/jats:p><\/jats:sec>","DOI":"10.1002\/iid3.1059","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T13:41:20Z","timestamp":1698241280000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of inflammatory factors and T\u2010cell subsets in the diagnosis of recurrence in epithelial ovarian cancer patients and the effect of olaparin treatment on them"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6839-4531","authenticated-orcid":false,"given":"Gulijianati","family":"Maowulieti","sequence":"first","affiliation":[{"name":"Department of Gynaecology, Wuxi Maternity and Child Health Care Hospital Women's Hospital of Jiangnan University, Jiangnan University Wuxi Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaojie","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, Wuxi Maternity and Child Health Care Hospital Women's Hospital of Jiangnan University, Jiangnan University Wuxi Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, Wuxi Maternity and Child Health Care Hospital Women's Hospital of Jiangnan University, Jiangnan University Wuxi Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, Wuxi Maternity and Child Health Care Hospital Women's Hospital of Jiangnan University, Jiangnan University Wuxi Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0047"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-021-00860-8"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00139-5"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-004149"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082357"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16411"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-003053"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30469-2"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00073-5"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.648652"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1055805"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.840610"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00521-2"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.681062"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/PSY.0000000000001129"},{"issue":"2","key":"e_1_2_9_19_1","article-title":"Circulating CD4(+) Treg, CD8(+) Treg, and CD3(+) \u03b3\u03b4 T cell subpopulations in ovarian cancer","volume":"59","author":"Li R","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04101-2"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad136"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-021-00845-6"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-023-01192-4"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101697"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2023.01.009"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109130"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030667"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076142"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.156051"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02668-9"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.11.054"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.034"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/iub.2048"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.01.027"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11233789"}],"container-title":["Immunity, Inflammation and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.1059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T08:06:35Z","timestamp":1698912395000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iid3.1059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1002\/iid3.1059"],"URL":"https:\/\/doi.org\/10.1002\/iid3.1059","archive":["Portico"],"relation":{},"ISSN":["2050-4527","2050-4527"],"issn-type":[{"type":"print","value":"2050-4527"},{"type":"electronic","value":"2050-4527"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"2023-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1059"}}